Launching and scaling the HYDROS Robotic System, the company's next-generation AI-powered robotic platform that delivers Aquablation therapy using AI-interpreted, real-time ultrasound imaging and advanced image-guided treatment planning.

Expected impact: Improves procedural consistency, reduces activation variability, and drives higher system placements and subsequent consumable handpiece sales.

Expanding the clinical utility of Aquablation therapy beyond benign prostatic hyperplasia (BPH) into localized prostate cancer through two major randomized clinical trials: WATER IV RP (versus radical prostatectomy) and WATER IV AS (versus active surveillance).

Expected impact: Establishes Aquablation as a viable, quality-of-life-preserving alternative to radical surgery and active surveillance, opening a massive new therapeutic market.

Restructuring the sales force, establishing a dedicated launch team to reduce hospital activation variability, and implementing a disciplined handpiece pricing strategy to align handpiece sales closely with actual procedure volumes.

Expected impact: Reduces field inventory levels, eliminates end-of-quarter purchasing incentives, improves average selling prices, and supports long-term margin expansion.